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While evidence supporting the hypothesis that blood purification improve outcome in septic acute kidney injury
(AKI) has not been established, many physicians hope to improve outcome in septic AKI by blood purification.
Elucidation of the pathophysiology of sepsis has revealed close involvement of humoral mediators, including
cytokines, pathogen-associated molecular patterns, and alarmins, in the development of severe sepsis. Removal of
substances by blood purification involves three major principles, namely filtration, dialysis (diffusion), and
adsorption. Multiple large randomized controlled trials (RCTs) of high-volume hemofiltration (HVHF) for patients
with AKI were conducted, but failed to prove the clinical efficacy of HVHF. Blood purification for the removal of
mediators through dialysis and filtration using a high cutoff (HCO) membrane hemofilter has not also been
established. Furthermore, a HCO membrane hemofilter shares a common problem with HVHF, which is excessive
removal of useful substances, such as antimicrobial agents and/or nutrients. Accordingly, continuous
hemodiafiltration using cytokine-adsorbing hemofilters (CAH-CHDF) such as polymethylmethacrylate (PMMA) and
AN69ST membrane hemofilters has been attracting attention recently. In this review, we report recent findings
regarding these old hemofilters with new applications. Although the number of in vitro and in vivo studies
conducted to date has been limited, the studies suggest a possibility that these modalities are useful particularly for
the treatment of septic shock and septic AKI. CAH-CHDF is expected to be recognized globally as a treatment of
septic shock and septic AKI in the near future.
Keywords: Cytokine, Adsorption, Sepsis, Renal replacement therapy, Continuous hemodiafiltration,
Polymethylmethacrylate, AN69 surface treated, Critical care, Non-renal indicationBackground
Improvement of outcome in acute kidney injury (AKI)
by renal replacement therapy (RRT) is an attractive hy-
pothesis. Although AKI is a common clinical condition
frequently encountered in the intensive care unit (ICU)
[1], a treatment with proven clinical efficacy in AKI has
not been established. As a consequence, treatment of
AKI mainly involves both treatment of the underlying
disease and support for renal function with renal re-
placement therapy. This is also the case with septic AKI
accounting for approximately half of AKI cases experi-
enced in the ICU [1]. The Surviving Sepsis Campaign
Guidelines (SSCG) [2], international guidelines for diagno-
sis and treatment of severe sepsis/septic shock, include* Correspondence: hat@shogo.com
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the SSCG contains nothing but weak recommendations
for the choice of intermittent hemodialysis and continu-
ous renal replacement therapy (CRRT). That is, the evi-
dence supporting the hypothesis that blood purification
improves outcome of septic AKI remains to be established
to date. However, many intensive care physicians and phy-
sicians involved in blood purification endorse this hypoth-
esis [3] and have been investigating blood purification
techniques that can improve the outcome of septic AKI.Why cytokine-adsorbing hemofilter?
Humoral mediators, including cytokines, are well known to
be deeply involved in the development of severe sepsis/sep-
tic shock [4]. In addition, production of these mediators
has been shown to be triggered by pathogen-associated
molecular patterns (PAMPs) including lipopolysaccharide
(LPS), as well as alarmins (which is produced by injuredle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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mobility group box-1 (HMGB-1) protein, to pattern recog-
nition receptors, such as toll-like receptor [6]. Accordingly,
these mediators, PAMPs and alarmins existing in the blood
stream are currently considered as target substances
for removal by blood purifications for the treatment
of septic AKI.
In 1993, Bellomo et al. first reported that various proin-
flammatory cytokines could be removed by continuous
venovenous hemofiltration (CVVH) with dialysis, namely
continuous hemodiafiltration (CHDF) [7]. Coincidentally,
we focused on the fact that CHDF using polymethyl-
methacrylate (PMMA) membrane hemofilter (known in
the field of chronic maintenance dialysis to efficiently re-
move β2-microglobulin (β2-MG) based on the principle of
adsorption [8–10]) in critically ill patients resulted in fa-
vorable responses such as rapid improvement of systemic
inflammation as well as increase in blood pressure and
urine output after initiation of CHDF. Such effects were
not obtained when other available membrane hemofilters
at that time, such as polysulfone (PS), polyacrylonitrile
(PAN), ethylene vinyl alcohol (EVAL), and cellulose tri-
acetate (CTA) were used. We therefore started to investi-
gate removal of mediators by CHDF [11] and reported the
clinical efficacy of PMMA-CHDF [12–14].
Other groups have also attempted application of RRT
to cytokine modulation for improvement of clinical con-
ditions in sepsis and AKI. Removal of substances by
blood purification involves three major principles,
namely filtration, dialysis (diffusion), and adsorption.
Among the three principles, filtration has been investi-
gated most extensively in the last two decades in the
form of a technique increasing filtration volumes (high-
volume hemofiltration (HVHF)). Ronco et al. conducted
a randomized controlled trial (RCT) that compared
therapeutic results of RRT in AKI at three different
treatment doses (20, 35, and 45 mL/kg/h) [15]. Results
demonstrated that the survival rate was higher in the 35
and 45 mL/kg/h groups than in the 20 mL/kg/h group.
Regarding patients with sepsis, the highest survival rate
was observed in the 45 mL/kg/h group. The impact of
this report was so great that many multicenter RCTs
were conducted to confirm the effect of HVHF. How-
ever, as large RCTs, such as the ATN [16], RENAL [17],
and IVOIRE [18] studies, failed to prove the clinical
efficacy of HVHF, HVHF in septic AKI is no longer
recommended in a recent consensus statement [19].
Removal of mediators with higher molecular weight
(MW) substances based on the principle of dialysis re-
quires enlargement of membrane pore size. Blood purifi-
cation for removal of mediators by dialysis and filtration
using a high cutoff (HCO) membrane with a larger pore
size has been reported by a particular group [20, 21].
While hemodiafiltration using a HCO membrane wasreported to exhibit a greater cytokine clearance than that
in a conventional membrane and have minimal problem-
atic side effects, no large RCT of this therapy has been
conducted and its efficacy has not been established to
date. As cytokine removal with a HCO membrane de-
pends on filtration volume and dialysis dose, removal
of useful substances, such as antimicrobial agents and
nutrients including albumin, considered a problem
with HVHF [22], may also be a drawback in this blood
purification technique.
As described earlier, the current situation is that the
efficacy of HVHF was negated and blood purification
with a HCO membrane has not yet been sufficiently
supported by RCTs. Furthermore, HCO membrane
shares a common problem with HVHF, which is the ex-
cessive removal of useful substances depending on their
MW. Accordingly, with mounting expectations for re-
moval of mediators based on the principle of adsorption,
cytokine-adsorbing hemofilter (CAH) made of membrane
materials with a high adsorption capacity for cytokines is
attracting attention from intensive care physicians [3].
Direct hemoperfusion using a polymyxin B endotoxin-
adsorbing column (PMX-DHP) has been developed in
Japan and widely applied for the treatment of septic
shock caused by gram negative bacteria for more than
20 years. Although hemodynamic improvement after
PMX-DHP treatment has been widely recognized, the effi-
cacy of this modality has not been established yet.
EUPHAS study [23], RCT for abdominal sepsis, demon-
strated the efficacy of PMX-DHP. However, high mortality
rate in the control group and the statistical method has
been criticized [24]. Furthermore, another RCT, ABDO-
MIX study [25] failed to prove the clinical efficacy of
PMX-DHP. The mortality rate in the treatment group was
higher than that of control group although they were not
statistically different [25]. In addition, PMX-DHP is more




The PMMA membrane is a synthetic polymeric mem-
brane prepared by immersing the hydrophobic matrix of
PMMA in water to replace with water the organic solv-
ent within the micropore space, utilizing a phenomenon
that mixing two methylmethacrylate polymer elements
with different tacticity (isotactic PMMA and syndiotactic
PMMA) in an organic solvent generates a thermorever-
sible gel [7]. After marketing authorization of the first
PMMA dialyzer in 1977, BK Series® was developed as a
newer product lineup with improved water permeability,
removal capacity of solutes and excellent biocompati-
bility, and has been widely used in the field of mainten-
ance dialysis. A PMMA membrane has a symmetric
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matrix. Its fractionation characteristic curve is broader
than that of other synthetic polymeric membranes, such
as PS membrane. It also has an advantage of greater
dialysance of middle-MW and high-MW substances
(e.g., albumin) compared with the conventionally used
cellulose membrane. Furthermore, the PMMA membrane
dialyzer was shown to have an excellent ability to remove
β2-MG (MW 11,800 Da), identified as a pathogenic sub-
stance of dialysis-related amyloidosis [26]. A subsequent
investigation revealed that the β2-MG level in the dialysate
was extremely low when a PMMA dialyzer (BK Series®)
was used for hemodialysis and that this phenomenon was
due to adsorption of β2-MG to PMMA membrane [27].
Another subsequent investigation demonstrated that
β2-MG was detectable in the filtrate after the adsorption
capacity of the PMMA dialyzer reached saturation level
over time [28].
As described earlier, the excellent adsorption characteris-
tics of the PMMA membrane has long been recognized. In
1986, continuous hemofiltration (CHF) was first introduced
in the Department of Emergency and Critical Care
Medicine, Chiba University Hospital (Chiba, Japan), using a
PMMA membrane hemofilter. To ensure both extended
filter life and higher removal capacity for solutes, CHF was
subsequently replaced by CHDF as the method of choice
for CRRT. Through clinical experiences with CHDF using a
PMMA membrane hemofilter (PMMA-CHDF) in many
critically ill patients, we realized a number of effects that
could not be explained as those of RRT alone. These in-
cluded reduction of abdominal pain and rapid improve-
ment of symptoms of inflammatory response in severe
acute pancreatitis, as well as an increased blood pressure
and urine volume in patients with acute renal failure soon
after initiation of PMMA-CHDF. These facts implied re-
moval of some pathogenic substance(s) related to organ
failure by PMMA-CHDF. Therefore, we started an exten-
sive investigation regarding the effects of removal of
various humoral mediators, including cytokines, by
PMMA-CHDF and the clinical application thereof, which
triggered investigations of PMMA-CHDF in other institu-
tions in Japan, by investigators inspired by this idea.
We performed PMMA-CHDF in various conditions
and found that the blood levels of various cytokines
were lower at the outlet of a hemofilter than at the inlet
side. On the other hand, cytokines in the filtrate were
scarcely detected, and a positive correlation was ob-
served between blood cytokine levels and the clearance
of cytokines by CHDF, which demonstrated that reduc-
tion in cytokine levels after hemofilter passage was due
to the removal by adsorption to the PMMA membrane
hemofilter [29]. Furthermore, a significant decrease of
blood cytokine level from the baseline was observed
3 days after initiation of PMMA-CHDF, but not afterCHDF using a hemofilter made of a non-PMMA mem-
brane material [29]. We further investigated and re-
ported that early PMMA-CHDF in addition to early
goal-directed therapy (EGDT) in 43 patients with septic
shock (mean acute physiology and chronic health evalu-
ation II (APACHE II) score, 29.4; mean sequential organ
failure assessment (SOFA) score, 13.7) achieved excellent
therapeutic results of recovery rate from shock, 90.7 %
and 28-day survival rate, 79.1 % [12]. Matsuda et al.
reported a case control study of CRRT in septic AKI
involving patients undergoing PMMA-CHDF as the case
group and those undergoing CHDF using a PAN mem-
brane hemofilter as the historical control group. They
reported a significantly higher survival rate in the PMMA-
CHDF group [30]. Sakamoto et al. comparatively investi-
gated the therapeutic effects of PMMA-CHDF (in 11 pa-
tients) and PAN-CHDF (in 7 patients) performed after
PMX-DHP. While no significant differences in APACHE
II and SOFA scores were observed between the two treat-
ment groups, the survival rate in the PMMA-CHDF group
was better than that in the PAN-CHDF group (90.9 vs.
42.9 %) with significant improvements of the serum plas-
minogen activator inhibitor-1(PAI-1), protein C, IL-6, and
N-arachidonoylethylethanolamine (AEA) [31]. Considering
that unlike an AN-69 membrane (described in detail later),
PAN membrane used in these studies has no sulfonate
group and does not efficiently adsorb humoral mediators
such as cytokines, these studies suggest the clinical useful-
ness of a PMMA hemofilter as a cytokine-adsorbing hemo-
filter despite limitations in study design and sample size.
A number of in vitro studies reported the cytokine
adsorbing characteristics of a PMMA membrane hemo-
filter. We performed in vitro concentrated perfusion ex-
periments by using ascites with high interleukin (IL)-6
levels to investigate changes in ascites IL-6 level. Results
demonstrated that when three different membrane ma-
terials (PMMA, CTA, and PS) were compared, the IL-6
removal rate for the PMMA membrane hemofilter was
by far greater than that for other membrane hemofilters
and IL-6 was scarcely detectable in the filtrate. When a
CTA or a PS membrane hemofilter was used, IL-6 could
be removed only at an efficiency lower than that with a
PMMA membrane hemofilter and IL-6 was detected in
the filtrate [32]. Furthermore, when direct perfusion of
ascites containing high IL-6 levels was performed with
these membrane hemofilters, a CTA membrane hemofil-
ter removed only 20 % of IL-6, whereas a PMMA mem-
brane filter removed almost 100 % of IL-6 after 3-h
perfusion [32]. These results prove that the PMMA
membrane adsorbed IL-6 at a high efficiency. In another
in vitro experiment using porcine blood with continuous
LPS injection to induce continuous cytokine production,
we measured the cytokine clearance of PMMA-CHDF
(membrane area, 1.0 m2; blood flow rate: QB, 80 mL/min;
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QD, 1000 mL/h) over 24 h. The mean 24-h clearance
values for TNF-α, IL-6, IL-8, and HMGB-1 were 11.4,
20.9, 17.8, and 11.2 mL/min, respectively. The cytokine-
removing effect of the PMMA membrane hemofilter was
maintained during a prolonged CHDF session, though
with a slight decrease observed after use for 24 h (unpub-
lished data). In addition, the cytokine levels in the filtrate
were low in this experiment as well, which confirmed that
cytokine removal with PMMA membrane was based on
the principle of adsorption. Because the production of cy-
tokines continues a few days in severe sepsis/septic shock,
it is very important that the ability to adsorb cytokines is
kept for long duration.
Tomisawa et al. compared the adsorption characteristics
of the PMMA membrane and polyester polymer alloy
(PEPA) membrane (both with comparable sieving coeffi-
cients) by using chymotrypsinogen (MW 25,000 Da) and
albumin (MW 66,000). The PMMA membrane exhibited
an adsorption rate approximately 20 % higher than that of
the PEPA membrane. In addition, the adsorption rate to
the PMMA membrane increased with an increase in filtra-
tion rate, while no such change was observed for the PEPA
membrane [33, 34]. Based on these findings, Tomisawa
et al. considered that the mechanism of adsorption to the
PMMA membrane might involve occlusion of protein mol-
ecules into pores open in a uniform and symmetric mem-
brane structure. This mechanism may affect water
permeability and filter life of PMMA membrane hemofilter.
Furthermore, because of the nature of its adsorptive prop-
erty, PMMA membrane hemofilter is prone to clogging in
critically ill patients. Therefore, it is recommended to re-
place a PMMA hemofilter every 24 h during the treatment.
AN69 surface-treated hemofilter
AN69 surface-treated (AN69ST) membrane is a derivative
of AN69 (native AN69), originally developed in 1969 as
the world’s first synthetic polymeric membrane, prepared
by surface treatment of polyethyleneimine (PEI). Native
AN69 is a copolymer of hydrophobic acrylonitrile and
hydrophilic sodium methallylsulfonate and has a symmet-
ric microporous structure. This is also the sole membrane
with a hydrogel structure and possesses extremely high
hydrophilicity. As AN69 is negatively charged due to sul-
fonate groups derived from methallylsulfonate monomers,
the AN69 membrane adsorbs cytokines via ionic bonding
between its sulfonate group and the amino group on the
surface of a cytokine molecule. As the AN69 membrane
has a hydrogel structure, adsorption to this membrane
is considered to take place not only on the membrane sur-
face but also within the bulk layer, thereby exhibiting a
high adsorption capacity. In fact, native AN69 membrane
is reported to adsorb a greater amount of humoral media-
tors such as cytokines compared with PS membrane [35].Gasche et al. performed CVVH using an AN69 mem-
brane hemofilter (AN69-CVVH) in seven patients and re-
ported removal of factor D (activating complement) by
adsorption [36]. De Vriese et al. performed AN69-CVVH in
15 patients with septic AKI and reported a rapid decrease
in blood cytokine levels and improvement in cardiac out-
put, pulmonary artery wedge pressure, and systemic vascu-
lar resistance [37]. However, cytokine levels, once reduced,
subsequently increased again during CVVH and the AN69
hemofilter had to be replaced once every 3 h. Kellum et al.
demonstrated that AN69-CVVH in a murine sepsis model
induced by cecal ligation and puncture suppressed an in-
crease in blood IL-6 level [38]. When Rogiers et al. per-
formed CVVH using either a PS or an AN69 membrane
hemofilter in dogs injected with endotoxin, significantly
higher cardiac output, stroke volume, and left ventricular
stroke work index were observed in the AN69 group [35].
Native AN69 membrane negatively charged even on
the membrane surface is known to generate bradykinin
in contact with blood. In particular, when a patient takes
angiotensin-converting enzyme (ACE) inhibitors, kini-
nase II that inactivates bradykinin is inhibited and causes
serious hypotension, which has been a serious disadvan-
tage of AN69 membrane. Partial coating of the surface
of the AN69 membrane with a biocompatible cation PEI
reduced the zeta potential on the contact surface be-
tween the membrane and blood, thereby reducing brady-
kinin production greatly, although not all patients were
free from this adverse event [39].
The AN69ST membrane is known to have excellent
anti-thrombogenicity as well. AN69/AN69ST membranes
have a hydrogel structure and are therefore highly
hydrophilic. Furthermore, the surface of the AN69ST
membrane can be coated with heparin by priming
with saline-containing heparin. As a consequence, the
anti-thrombogenicity of the AN69ST membrane exceeds
that of the native AN69 membrane and anticoagulant-free
hemodialysis using AN69ST membrane has been reported
[40, 41]. On the other hand, as the sulfonyl groups on the
AN69 membrane adsorb nafamostate mesilate, this anti-
coagulant is not compatible enough with the AN69/
AN69ST membrane [42]. Appropriate priming is most
important and unfractionated heparin or low molecular
weight heparin is recommended if possible. If nafamostate
mesilate is the only anticoagulant to use e.g., trauma pa-
tient, it should be infused from not only pre-hemofilter
but also post-hemofilter.
Reports of basic research on the cytokine-adsorbing
capacity of the AN69ST membrane and clinical studies
of this membrane are limited. Yumoto et al. compared
four different membrane hemofilter, (AN69ST, PMMA,
HCO polyarylethersulfone; PAES, and PS) concerning the
capacity to remove HMBG1 in vitro. AN69ST had the
highest efficiency of HMBG1 removal, followed by the
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tle amount of HMGB-1 [43]. In a clinical study, Shiga
et al., conducted a single-arm multicenter study involving
CHDF using a AN69ST membrane hemofilter (SepXiris®)
in 34 patients with severe sepsis and septic shock associ-
ated with hyperlactatemia (blood lactate >36 mg/dL). Even
in very severe critically ill patients (mean APACHE II
score, 32.7 ± 9.8), the 28-day survival rate was as high as
73.5 % (Fig. 1) [44]. Based on these results, CHDF using
an AN69ST hemofilter in severe sepsis was formally ap-
proved by the National Health Insurance System in Japan
since July 2014, as a non-renal indication.
Modified AN69ST (oXiris®)
The oXiris® is a hemofilter using the AN69 membrane with
PEI surface coating and immobilized heparin. Compared
with the AN69ST membrane, the oXiris® has 3 times
greater amount of PEI surface coating (in the second layer)
and 10 times greater amount of pre-immobilized heparin
(in the third layer). As a consequence, oXiris® has excellent
anti-thrombogenicity and is capable of adsorbing endotoxin
(supposed to be negatively charged) to cationic PEI in the
second layer [45]. Bottom bulk layer of the oXiris® mem-
brane remains negatively charged and thereby retains its
ability to adsorb cytokines. That is, the oXiris® membrane
is intended to adsorb both endotoxin and cytokines.
In vitro experiments by Rimmele et al. that compared
the ability to adsorb cytokines (TNF-α, IL-18, IL-6, and
IL-1Ra) among three different membranes (PS, AN69,Fig. 1 Comparison of predicted survival, observed 28-day survival and the
according to the APACHE II score. O/P ratio: observed survival rate divided by
H, Nishida O, Oda S, Nakamura M, Mashiko K, Matsuda K, Kitamura N, Kikuchi
Hemofilter in Patients with Septic Shock: A Preliminary Report. Blood Purif 201and oXiris®) demonstrated that the AN69 and oXiris®
membranes adsorb cytokines substantially, while the PS
membrane adsorbs little cytokines. Furthermore, the
oXiris® adsorbed more cytokines and endotoxin than the
AN69 membrane [45]. When 6-h HVHF was performed
in a porcine model of sepsis by using either an AN69 or
oXiris® membrane hemofilter, the blood endotoxin level
was significantly lower in the oXiris® group. In addition,
the values of crystalloid infusion volume, colloid infusion
volume, degree of lactic acidosis, and pulmonary arterial
pressure were significantly lower in the oXiris® group [45].
We measured cytokine clearance of oXiris®-CHDF (mem-
brane area, 1.5 m2; QB, 80 mL/min; QF, 300 mL/h; QD,
1000 mL/h) over 24 h, using porcine blood with LPS con-
tinuous injection to induce continuous cytokine production.
The mean 24-h clearance values for TNF-α, IL-6, IL-8, and
HMGB-1 were 15.2, 18.3, 25.3, and 23.5 mL/min, respect-
ively. The sieving coefficients for these cytokines were all
less than 0.02, and removal by filtration was negligible [46].
While the clinical effects of the oXiris® membrane
hemofilter have scarcely been reported, Shum et al. per-
formed oXiris®-CVVH in six patients with septic AKI
and compared with 24 severity-matched historical con-
trols undergoing PS-CVVH. Results demonstrated that
the SOFA score after 48-h CVVH was reduced from the
value at ICU admission by 38 % in the oXiris® group,
while an increase of 3 % was observed in the control
group. No significant difference was observed in ICU
and in-hospital mortality between the two groups [47].observed/predicted survival ratio among the subgroups stratified
predicted survival rate. Image originally published in Shiga H, Hirasawa
Y, Fuke N, Continuous Hemodiafiltration with a Cytokine-Adsorbing
4;38:211-218. Image copyright Karger AG. All rights reserved
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oXiris®-CVVH and PMX-DHP in patients with septic
shock is currently in progress (ENDoX study). Further-
more, Honore et al. state in their review article that they
are planning an RCT to compare four different mem-
brane hemofilters (AN69, AN69ST, oXiris®, and PAES)
in septic shock with AKI [48].
Future perspectives of CAH-CHDF
The concept of CAH and treatment based on this concept
has been investigated mainly in Japan by using a PMMA
hemofilter. Accordingly, the Japanese Guidelines for the
management of sepsis [49] include a weak recommenda-
tion for CHDF for mediator removal, with a comment that
there is a possibility to improve hemodynamics, though
without sufficient evidence supporting improving out-
come. While potentials of the AN69ST and oXiris® hemo-
filters with excellent adsorption capacity for cytokines
have been recently attracting the attention of ICU physi-
cians in Europe and the USA, evidence for these modal-
ities are obviously lacking. Many clinical studies, including
large-scale RCTs, are expected to be planned, and some
clinical trials are currently ongoing.
What is necessary for establishing the clinical efficacy
of CAH-CHDF for the treatment of severe sepsis and
septic AKI in the future, in other words, what is neces-
sary for obtaining positive results in clinical trials to be
planned in the future? Adsorption is more efficient at
higher concentrations of the target substance in the blood.
Consequently, the effects of mediator removal using CAH
may be demonstrated more clearly in patients treated at
higher concentration of mediators such as cytokines. Since
we introduced a rapid IL-6 assay system into the clinical
laboratory of Chiba University Hospital in April 2000, we
have measured blood IL-6 level in various clinical condi-
tions and reported that blood IL-6 levels reflect theTable 1 Backgrounds of the patients in the previous reports
Author Nakada [12] Sakamoto [31
Publication year 2008 2008
Hemofilter PMMA PMMA
Number of patients 43 11
Age 63.5 ± 13.3 63.2 ± 10.8
APACHE II score 29.4 ± 8.4 24.8 ± 8.6
SOFA score 13.7 ± 3.7 9.7 ± 4.1
Lactate, mg/dL 72.2 ± 40.4 NA
Interleukin-6, pg/mL 132300 ± 243700 7893.8 ± 1023
Predicted survival ratea, % 32.8 NA
28-day survival rate, % 79.1 90.9
Data are presented as mean ± SD or median (interquartile range)
aSurvival rate calculated by APACHE II score
bSurvival rate at ICU discharge
NA not available, APACHE acute physiology and chronic health evaluation, SOFA seqseverity of systemic inflammatory response syndrome
(SIRS) and sepsis and increased blood IL-6 level is closely
associated with severity of organ dysfunction [50]. There-
fore, we consider that selective application of CAH-CHDF
to critically ill patients with hypercytokinemia based on
the measurement of blood IL-6 level is crucial to obtain
better therapeutic effect.
In the study of Nakada et al. that investigated the useful-
ness of PMMA-CHDF for septic shock, the subjects were
very critically ill patients as indicated by the following clin-
ical parameters: mean blood IL-6 level, 132,300 pg/mL
(median, 23,480 pg/mL); mean APACHE II score, 29.4;
mean SOFA score, 13.7; and mean blood lactate level,
72.2 mg/dL [12]. The single-arm study of AN69ST-CHDF
by Shiga et al. exclusively included subjects of severe sep-
sis/septic shock with a blood lactate level more than
36 mg/dL(4 mmol/L). Their clinical parameters indicated
the following severe clinical conditions: mean blood IL-6
level, 44,800 pg/mL; mean APACHE II score, 32.7; and
mean blood lactate level, 69.0 mg/dL. The subjects of the
oXiris®-CVVH study by Shum et al. had a median APA-
CHE II score of 36 (Table 1) [47]. Consequently, the selec-
tion of subjects based on actual measurements of humoral
mediators such as IL-6 may be the key in clinical studies
of CAH to be planned in the future. IL-6 is relatively
stable in blood, and an automated assay system that can
rapidly measure blood IL-6 level in approximately 30 min
is commercially available. We currently utilize a rapid
assay of IL-6 (Roche Diagnostics GmbH, Mannheim,
Germany) for determination of a treatment strategy for se-
vere sepsis and septic shock and for evaluation of treat-
ment effects. To measure blood IL-6 levels enable to
decide implementation of CAH-CHDF earlier before AKI
become obvious. In our institute, the cutoff value to initi-
ate CAH-CHDF is 10,000 pg/mL because IL-6 blood level




63.9 ± 12.3 67.1 ± 12.1 61 (51–67)
29.0 ± 6.7 32.7 ± 9.8 36 (28–41)
13.0 ± 3.7 NA NA
NA 69.0 ± 49.4 NA
8.4 NA 44800 ± 77700 NA
35.6 20.3 15 (8–36)
83.3 73.5 66.7b
uential organ failure assessment
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[50]. However, some cases with high SOFA score whose
IL-6 blood level is between 1000 and 10,000 pg/mL
indicate poor outcomes [50] so that we consider to imple-
ment CAH-CHDF in also such cases.
In brief, we believe that the patient selection for CAH-
CHDF based on actual measurements of mediators such
as IL-6 will be the key to successful clinical application
of CAH. If this is impossible, exclusive selection of most
critically ill patients using clinical parameters such as
the APACHE II and SOFA score, or blood lactate level
would be favorable.Conclusions
It is interesting that classical hemofilters based on the
PMMA (approved in 1977) and AN69 membranes
(developed in 1969) have played new roles in cytokine
removal by adsorption and control of hypercytokinemia
and are thereby attracting attention again in the twenty-
first century. Today is the scholar of yesterday (“on-ko chi-
shin” in Japanese). Some of in vitro and in vivo studies
suggest a possibility that these old modalities with new
applications may be particularly useful in the treatment of
septic shock and septic AKI. It is important to understand
the characteristics of individual hemofilters and to select a
patient to whom CAHs are clinically beneficial based on
the appropriate method. We expect that CAH-CHDF will
be recognized globally as an option for the treatment of
septic shock and septic AKI in the near future.
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